LifeStance Health Group, Inc. (NASDAQ:LFST) Insider Sells $95,040.00 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) insider Ujjwal Ramtekkar sold 16,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $5.94, for a total transaction of $95,040.00. Following the completion of the transaction, the insider now directly owns 113,435 shares in the company, valued at approximately $673,803.90. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

LifeStance Health Group Trading Down 2.1%

Shares of NASDAQ LFST opened at $5.60 on Thursday. LifeStance Health Group, Inc. has a twelve month low of $4.64 and a twelve month high of $8.61. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The company’s fifty day moving average is $6.19 and its 200-day moving average is $7.05. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -21.54 and a beta of 1.22.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of LifeStance Health Group by 5.0% during the first quarter. Vanguard Group Inc. now owns 11,221,237 shares of the company’s stock worth $74,733,000 after acquiring an additional 531,841 shares during the period. Jennison Associates LLC raised its holdings in shares of LifeStance Health Group by 2.1% during the first quarter. Jennison Associates LLC now owns 8,255,236 shares of the company’s stock worth $54,980,000 after acquiring an additional 168,856 shares during the period. Wellington Management Group LLP raised its holdings in shares of LifeStance Health Group by 2.3% during the first quarter. Wellington Management Group LLP now owns 5,399,293 shares of the company’s stock worth $35,959,000 after acquiring an additional 123,056 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of LifeStance Health Group by 87.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company’s stock worth $25,977,000 after acquiring an additional 1,643,390 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of LifeStance Health Group by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 3,465,471 shares of the company’s stock worth $25,546,000 after acquiring an additional 13,293 shares during the period. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on LFST. UBS Group raised shares of LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $8.50 price objective on the stock in a research note on Tuesday, May 27th. Canaccord Genuity Group assumed coverage on shares of LifeStance Health Group in a research report on Thursday, April 3rd. They set a “buy” rating and a $8.00 price target on the stock. William Blair reissued an “outperform” rating on shares of LifeStance Health Group in a research report on Friday, February 28th. Finally, KeyCorp assumed coverage on shares of LifeStance Health Group in a research report on Tuesday, April 8th. They set an “overweight” rating and a $9.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, LifeStance Health Group has a consensus rating of “Moderate Buy” and an average price target of $8.50.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.